Compare TGTX & ASR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGTX | ASR |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | Mexico |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.8B |
| IPO Year | 2008 | 2001 |
| Metric | TGTX | ASR |
|---|---|---|
| Price | $64.36 | $266.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $69.43 | ★ $324.22 |
| AVG Volume (30 Days) | ★ 1.8M | 41.3K |
| Earning Date | 11-09-2026 | 10-22-2026 |
| Dividend Yield | N/A | ★ 3.71% |
| EPS Growth | ★ 1746.67 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $2,785,000.00 | N/A |
| Revenue This Year | $61.95 | $6.96 |
| Revenue Next Year | $35.55 | $23.46 |
| P/E Ratio | $120.60 | ★ $18.58 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.76 | $226.19 |
| 52 Week High | $68.03 | $381.52 |
| Indicator | TGTX | ASR |
|---|---|---|
| Relative Strength Index (RSI) | 60.53 | 59.46 |
| Support Level | $52.12 | $257.47 |
| Resistance Level | $63.60 | $268.00 |
| Average True Range (ATR) | 3.52 | 5.30 |
| MACD | 0.14 | 0.36 |
| Stochastic Oscillator | 64.62 | 63.05 |
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Grupo Aeroportuario del Sureste SAB de CV and its subsidiaries hold concessions to operate, maintain, and develop airports in the southeast region of Mexico. As an operator of airports, it charges airlines, passengers, and other users fees for using the airports' facilities. The group also derives rental and other income from commercial activities conducted at its airports, such as the leasing of space to restaurants and retailers. The company's operating segments are Cancun, which generates majority revenue, Aerostar, Airplan, Merida, Villahermosa, Holding and Services, and Others.